Innovations in Genetics

Welcome to our literature update on laboratory biomarker developments in major diseases. In our third edition, we highlight innovative advancements in genetics:

The rapid progression in the field of genetics has ushered in an era of unprecedented diagnostic capacities. With the expanded availability of genetic testing, we can pinpoint genetic predilections for a myriad of conditions, notably cardiovascular diseases, cancer, and infectious diseases. Central to these advancements is precision medicine, a concept that propounds treatment tailored to individual genetic blueprints, hand-in-hand with personalised medicine, which considers a patient's unique genetic, environmental, and lifestyle mosaic.

The combination of genetics and computational biology allows for the interpretation of vast datasets, translating them into actionable clinical insights. Yet challenges loom. Ethical dilemmas, data security, interpretation accuracy, and equitable access remain pressing concerns. Addressing these will be pivotal in truly harnessing genetics for the betterment of all.

Recent key publications
 

1) Genetic Diagnostics in Everyday Clinical Practice in Child and Adolescent Psychiatry: Indications, Framework Conditions, Hurdles, and Proposed Solutions. Z Kinder Jugendpsychiater Psychother 2023; Degenhardt F, Wohlleber E, Jamra RA, Hebebrand J.

  Link to full article

Exploring the rise of genetic testing in child and adolescent psychiatry in Germany: The guidelines, the challenges, and the transformative potential for patient care.

2) Molecular pathology of colorectal cancer. Pathologie (Heidelb) 2023; 44:279-286. Woischke C, Michl M, Neumann J.

  Link to full article

We are on the brink of a sea change: Individualised therapies, anchored by novel molecular markers, are about to redefine how we tackle colorectal carcinoma.

3) Current status of molecular diagnostic approaches using liquid biopsy. J Gastroenterol 2023; 58:834-847. Takahashi K, Takeda Y, Ono Y et al.

  Link to full article

Revolution is underway: Liquid biopsies are on the cusp of transforming early diagnosis in pancreatic cancer, harnessing the power of genetic insights to chart patient-specific paths and outcomes.

4) CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn 2023; 25:619-629. Pratt VM, Cavallari LH, Fulmer ML et al.

  Link to full article

Charting the path for standardised pharmacogenomics testing, delve into the Association for Molecular Pathology's new recommendations on essential gene variants for clinical CYP3A4 and CYP3A5 drug-response assays.

5) State-of-the-Art Molecular Genetics and Genomics in Germany. Int J Mol Sci 2023; 24. Lukas J.

  Link to full article

Discover Germany's cutting-edge contributions in genetics and genomics, as this Special Issue delves deep into disease mechanisms, innovative therapies, and the game-changing roles of molecules like PTEN in precision medicine and beyond.

6) Cellular and molecular biology of sirtuins in cardiovascular disease. Biomed Pharmacother 2023; 164:114931. Liu YP, Wen R, Liu CF et al.

  Link to full article

Unlocking the heart of cardiovascular health: Dive into the pivotal roles of Sirtuins (SIRTs) in cardiovascular disease pathways and the promising therapeutic interventions they herald for the future.

7) Selection and Interpretation of Molecular Diagnostics in Heart Transplantation. Circulation 2023; 148:679-694. Goldberg JF, Truby LK, Agbor-Enoh S et al.

  Link to full article

Despite rising heart transplant numbers, patient survival remains stagnant; explore the innovative diagnostic tools and the insights from genetics that might reshape post-transplant care and outcomes.

8) Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization. Arthritis Rheumatol 2023; 75:1781-1792. Zheng J, Wheeler E, Pietzner M et al.

  Link to full article

Challenging the safety profile: Our genetic study suggests that while romosozumab targets osteoporosis, reducing sclerostin might inadvertently heighten the risks of cardiovascular issues and type 2 diabetes.

9) ADAMTS-7 Modulates Atherosclerotic Plaque Formation by Degradation of TIMP-1. Circ Res 2023; 133:674-686. Sharifi MA, Wierer M, Dang TA et al.

Link to full article

Diving deep into atherosclerosis: Unpacking how ADAMTS-7 affects plaque stability through TIMP-1 and exploring potential interventions to bolster cardiovascular health.